Acerus terminates NATESTO contract with Endo Ventures
Canadian pharmaceutical company Acerus announced last week that its contract with Endo Ventures Bermuda Limited to commercialize NATESTO, a testosterone replacement nasal gel, will be terminated effective June 30. Read More »
Alerts Sign-up